Results 271 to 280 of about 881,500 (386)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. [PDF]

Heart
Pang L, Xia Y, Tang M, Ma M, Ran H, Zhao Z, Wang T, Yang J, Li J, Zhou Y, Duo L, Luo Z, Zhu D.   +12 more
europepmc   +1 more source

Fen-phen and Valvular Heart Disease

, 1998
Alen N. Cohen
openalex   +1 more source

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Valvular Heart Disease: Geography Is Destiny! [PDF]

JACC Adv
Bakaeen FG, Jaber W, Kaur S.
europepmc   +1 more source

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Circulation, 2014
Rick A. Nishimura, C. Otto, R. Bonow, B. Carabello, J. Erwin, R. Guyton, P. O'Gara, C. Ruiz, N. Skubas, P. Sorajja, T. Sundt, James D. Thomas   +11 more
semanticscholar   +1 more source

The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review

ESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler, Malcolm Brown, Philippe Prokocimer, Ashley C. Humphries, Sophie Pope, Olivia Wright, Jun Su, Osama Elnawasany, Bogdan Muresan   +8 more
wiley   +1 more source

Burden of non-rheumatic valvular heart disease globally and in China from 1990 to 2021: a systematic analysis for the global burden of disease study 2021. [PDF]

Front Cardiovasc Med
Chen W, Wei J, Zheng X, Lan Y, Zheng B.
europepmc   +1 more source

Recent highlights from the <i>International Journal of Cardiology</i>: <i>Heart & Vasculature</i>: Valvular heart disease. [PDF]

Int J Cardiol Heart Vasc
Pelliccia F, Dziewierz A, Zimarino M, Dobrev D.   +3 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source